The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
Open accessAbstract
BACKGROUND: Some cancer patients are immuno-compromised, and it has been long felt that immune-intervention is not compatible with standard chemotherapies. However, increasing evidence suggests that standard chemotherapy drugs may stimulate beneficial changes in both the immune system and tumour. METHODS: We have assessed the expression of human leucocyte antigen class 1 (HLA1) on tumour cells before and after chemotherapy agents (cyclophosphamide, oxaliplatin or gemcitabine). In addition, we show that chemotherapy-stressed tumour cells may release cytokines that enhance the interactions between dendritic cells (DCs) and T cells into growth media. RESULTS: Here we report that some chemotherapy agents can increase HLA1 expression in tumour cells, even when expression is low. Increases were associated with killing by cytotoxic T cells, which were negated by HLA1-blockade. Furthermore, T-cell function, as indicated by increased proliferation, was enhanced as supernatants derived from tumours treated with chemotherapy augmented DC-maturation and function. CONCLUSION: There is evidence that a facet of immune surveillance can be restored by appropriate chemotherapy agents. Also, tumours exposed to some chemotherapy may secrete cytokines that can mature DCs, which ultimately enhances T-cell responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
The Dendritic Cell System and its Role in Immunogenicity
Steinman, R. M. (1991) · Annual Review of Immunology · doi:10.1146/annurev.iy.09.040191.001415 · Cited by 4,658
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,127
Fotakis, G., & Timbrell, J. A. (2006) · Toxicology Letters · doi:10.1016/j.toxlet.2005.07.001 · Cited by 1,558
Jonuleit, H., Kühn, U., Müller, G., Steinbrink, K., Paragnik, L., Schmitt, E., Knop, J., & Enk, A. H. (1997) · European Journal of Immunology · doi:10.1002/eji.1830271209 · Cited by 1,163
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Does the Immune System See Tumors as Foreign or Self?
Pardoll, D. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141135 · Cited by 753
Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution
Lyons, A. B. (2000) · Journal of Immunological Methods · doi:10.1016/s0022-1759(00)00231-3 · Cited by 684
Chronic immune activation and inflammation as the cause of malignancy
O'Byrne, K. J., & Dalgleish, A. G. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1943 · Cited by 543
Self-citationBronte, V., Apolloni, E., Cabrelle, A., Ronca, R., Serafini, P., Zamboni, P., Restifo, N. P., & Zanovello, P. (2000) · Blood · doi:10.1182/blood.v96.12.3838 · Cited by 527
Natural history of HLA expression during tumour development
Garrido, F., Cabrera, T., Concha, A., Glew, S., Ruiz-Cabello, F., & Stern, P. L. (1993) · Immunology Today · doi:10.1016/0167-5699(93)90264-l · Cited by 448
Comparison of the LDH and MTT assays for quantifying cell death: validity for neuronal apoptosis?
Lobner, D. (2000) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(99)00193-4 · Cited by 394
de Vries, I. J. M., Lesterhuis, W. J., Scharenborg, N. M., Engelen, L. P. H., Ruiter, D. J., Gerritsen, M. P., Croockewit, S., Britten, C. M., Torensma, R., Adema, G. J., et al. (2003) · PubMed · Cited by 327
Monoclonal antibodies for cancer immunotherapy
Weiner, L. M., Dhodapkar, M. V., & Ferrone, S. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60251-8 · Cited by 307
Is cancer dangerous to the immune system?
Fuchs, E. J., & Matzinger, P. (1996) · Seminars in Immunology · doi:10.1006/smim.1996.0035 · Cited by 289
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2002) · PubMed · Cited by 238
Part I: Vaccines for solid tumours
Mocellin, S., Mandruzzato, S., Bronte, V., Lise, M., & Nitti, D. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01610-9 · Cited by 196
Schiavoni, G., Mattei, F., Di Pucchio, T., Santini, S. M., Bracci, L., Belardelli, F., & Proietti, E. (2000) · Blood · doi:10.1182/blood.v95.6.2024 · Cited by 196
Key cancer cell signal transduction pathways as therapeutic targets
Bianco, R., Melisi, D., Ciardiello, F., & Tortora, G. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.07.034 · Cited by 179
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
Plate, J. M. D., Plate, A. E., Shott, S., Bograd, S., & Harris, J. E. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0638-1 · Cited by 176
Chronic immune activation and inflammation in the pathogenesis of aids and cancer
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)84008-8 · Cited by 166
Immune-Potentiating Effects of the Chemotherapeutic Drug Cyclophosphamide
Brode, S., & Cooke, A. (2008) · Critical Reviews™ in Immunology · doi:10.1615/critrevimmunol.v28.i2.20 · Cited by 165
Harnessing the immune system to treat cancer
Bhardwaj, N. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32136 · Cited by 152
Epigenetic regulation of immune escape genes in cancer
Tomasi, T. B., Magner, W. J., & Khan, A. N. H. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0164-4 · Cited by 142
Role of Altered Expression of HLA Class I Molecules in Cancer Progression
Aptsiauri, N., Cabrera, T., Méndez, R., Garcia-Lor, A., Ruiz‐Cabello, F., & Garrido, F. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72005-0_13 · Cited by 132
Class I-induced resistance to natural killing: identification of nonpermissive residues in HLA-A2.
Storkus, W. J., Salter, R. D., Alexander, J., Ward, F. E., Ruiz, R., Cresswell, P., & Dawson, J. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.14.5989 · Cited by 126
Overview of Tumor Cell–Based Vaccines
Copier, J. P., & Dalgleish, A. G. (2006) · International Reviews of Immunology · doi:10.1080/08830180600992472 · Cited by 126
Self-citationAnalysis of HLA expression in human tumor tissues
Cabrera, T., López‐Nevot, M. Á., Gaforio, J. J., Ruiz‐Cabello, F., & Garrido, F. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-002-0332-0 · Cited by 119
Inflammation and Cancer: The role of the immune response and angiogenesis
Dalgleish, A. G., & O'Byrne, K. J. (2006) · Cancer treatment and research · doi:10.1007/0-387-26283-0_1 · Cited by 91
Self-citationReview article: immune suppression and colorectal cancer
Evans, C., Dalgleish, A. G., & Kumar, D. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03075.x · Cited by 91
Self-citationSelective MHC expression in tumours modulates adaptive and innate antitumour responses
Rees, R. C., & Mian, S. (1999) · Cancer Immunology Immunotherapy · doi:10.1007/s002620050589 · Cited by 90
Translating basic cancer research into new cancer therapeutics
Workman, P., & Kaye, S. B. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02319-5 · Cited by 74
The effect of irradiation on expression of HLA class I antigens in human brain tumors in culture
Klein, B., Loven, D., Lurie, H., Rakowsky, E., Nyska, A., Levin, I., & Klein, T. (1994) · Journal of neurosurgery · doi:10.3171/jns.1994.80.6.1074 · Cited by 61
Targeting the Immune System in Cancer
Chaudhuri, D., Suriano, R., Mittelman, A., & Tiwari, R. K. (2009) · Current Pharmaceutical Biotechnology · doi:10.2174/138920109787315114 · Cited by 61
Liu, W. M., Scott, K. A., Shamash, J., Joel, S., & Powles, T. B. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802239188 · Cited by 59
Self-citationLiu, W. M. (2008) · Current Clinical Pharmacology · doi:10.2174/157488408784293714 · Cited by 20
Self-citation
Cited by
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Pitt, J. M., Marabelle, A., Eggermont, A., Soria, J.-C., Kroemer, G., & Zitvogel, L. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw168 · Cited by 1,338
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Therapeutic vaccines for cancer: an overview of clinical trials
Melero, I., Gaudernack, G., Gerritsen, W., Huber, C., Parmiani, G., Scholl, S., Thatcher, N., Wagstaff, J., Zielinski, C., Faulkner, I., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.111 · Cited by 776
Metadata
- Authors
- Liu, W. M., Fowler, D. W., Smith, P., & Dalgleish, A. G.
- Venue
- British Journal of Cancer
- Published
- 2009-12-08
- Volume
- 102
- Issue
- 1
- Pages
- 115-123
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1980980429
- Cited by
- 356
- References
- 38
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.